Showing 3,041 - 3,060 results of 11,883 for search '(( significant effects decrease ) OR ( significantly ((linked decrease) OR (linear decrease)) ))', query time: 0.56s Refine Results
  1. 3041
  2. 3042
  3. 3043
  4. 3044

    PRISMA flow chart of the screening process. by Mohamed R. Abdelraouf (21501468)

    Published 2025
    “…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
  5. 3045

    Forest plot of liver function tests. by Mohamed R. Abdelraouf (21501468)

    Published 2025
    “…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
  6. 3046

    Subgroup analysis of BUN based on pump type. by Mohamed R. Abdelraouf (21501468)

    Published 2025
    “…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
  7. 3047

    Subgroup analysis of ICU Stay based on pump type. by Mohamed R. Abdelraouf (21501468)

    Published 2025
    “…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
  8. 3048

    Subgroup analysis of eGFR based on pump type. by Mohamed R. Abdelraouf (21501468)

    Published 2025
    “…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
  9. 3049

    GRADE evidence profile. by Mohamed R. Abdelraouf (21501468)

    Published 2025
    “…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
  10. 3050

    Characteristics of included studies. by Mohamed R. Abdelraouf (21501468)

    Published 2025
    “…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
  11. 3051

    Sensitivity analysis for eGFR. by Mohamed R. Abdelraouf (21501468)

    Published 2025
    “…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
  12. 3052

    Sensitivity analysis for BUN. by Mohamed R. Abdelraouf (21501468)

    Published 2025
    “…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
  13. 3053

    Subgroup analysis of BUN based on surgery type. by Mohamed R. Abdelraouf (21501468)

    Published 2025
    “…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
  14. 3054

    Baseline Characteristics of Included Patients. by Mohamed R. Abdelraouf (21501468)

    Published 2025
    “…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
  15. 3055
  16. 3056

    Image 1_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.pdf by Kai Sun (140584)

    Published 2025
    “…Background<p>Charged Multivesicular Body Protein 4A (CHMP4A), a member of the ESCRT-III family, plays a pivotal role in membrane remodeling and fission, with emerging evidence underscoring its significance in cancer immunotherapy. The complex pathogenesis and therapeutic resistance characteristic of liver hepatocellular carcinoma (LIHC) present significant challenges in clinical practice. …”
  17. 3057

    Table 1_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.docx by Kai Sun (140584)

    Published 2025
    “…Background<p>Charged Multivesicular Body Protein 4A (CHMP4A), a member of the ESCRT-III family, plays a pivotal role in membrane remodeling and fission, with emerging evidence underscoring its significance in cancer immunotherapy. The complex pathogenesis and therapeutic resistance characteristic of liver hepatocellular carcinoma (LIHC) present significant challenges in clinical practice. …”
  18. 3058

    Table 2_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.docx by Kai Sun (140584)

    Published 2025
    “…Background<p>Charged Multivesicular Body Protein 4A (CHMP4A), a member of the ESCRT-III family, plays a pivotal role in membrane remodeling and fission, with emerging evidence underscoring its significance in cancer immunotherapy. The complex pathogenesis and therapeutic resistance characteristic of liver hepatocellular carcinoma (LIHC) present significant challenges in clinical practice. …”
  19. 3059

    Image 2_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.pdf by Kai Sun (140584)

    Published 2025
    “…Background<p>Charged Multivesicular Body Protein 4A (CHMP4A), a member of the ESCRT-III family, plays a pivotal role in membrane remodeling and fission, with emerging evidence underscoring its significance in cancer immunotherapy. The complex pathogenesis and therapeutic resistance characteristic of liver hepatocellular carcinoma (LIHC) present significant challenges in clinical practice. …”
  20. 3060